Literature DB >> 7979309

Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus Study Group.

S R Scriver1, S L Walmsley, C L Kau, D J Hoban, J Brunton, A McGeer, T C Moore, E Witwicki.   

Abstract

Susceptibility testing of 1,688 Haemophilus influenzae isolates found 484 ampicillin-resistant strains; 474 strains (28.4%) were beta-lactamase positive, and 5 strains (0.4%) were non-beta-lactamase producers. Restriction enzyme digestion of the beta-lactamase amplicon determined that, of 157 strains, 11 (7.0%) contained ROB-1 beta-lactamase and 146 (93.0%) contained a TEM-type beta-lactamase.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7979309      PMCID： PMC284617          DOI： 10.1128/AAC.38.7.1678

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Canadian Study Group.

Authors:  L D Tremblay; J L'Ecuyer; P Provencher; M G Bergeron
Journal:  CMAJ       Date:  1990-11-01       Impact factor: 8.262

2.  Sequence analysis and evolutionary perspectives of ROB-1 beta-lactamase.

Authors:  J M Juteau; R C Levesque
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 3.  Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae.

Authors:  J H Jorgensen
Journal:  Clin Infect Dis       Date:  1992-05       Impact factor: 9.079

4.  Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322.

Authors:  J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

5.  The pathogenicity of Haemophilus influenzae.

Authors:  D C Turk
Journal:  J Med Microbiol       Date:  1984-08       Impact factor: 2.472

6.  R-factor mediated beta-lactamase production by Haemophilus influenzae.

Authors:  R B Sykes; M Matthew; C H O'Callaghan
Journal:  J Med Microbiol       Date:  1975-08       Impact factor: 2.472

7.  Ampicillin treatment failure of apparently beta-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase.

Authors:  L G Rubin; A A Medeiros; R H Yolken; E R Moxon
Journal:  Lancet       Date:  1981-11-07       Impact factor: 79.321

8.  Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group.

Authors:  S R Scriver; D E Low; A E Simor; B Toye; A McGeer; R Jaeger
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

9.  Epidemiology of rob beta-lactamase among ampicillin-resistant Haemophilus influenzae isolates in the United States.

Authors:  R S Daum; M Murphey-Corb; E Shapira; S Dipp
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

10.  beta-Lactamases and beta-lactam resistance in Escherichia coli.

Authors:  G A Jacoby; L Sutton
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191
  10 in total
  28 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

3.  A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens.

Authors:  R J Davidson; D E Low
Journal:  Can J Infect Dis       Date:  1999-03

4.  Epidemiology and evolution of antibiotic resistance of Haemophilus influenzae in children 5 years of age or less in France, 2001-2008: a retrospective database analysis.

Authors:  H Dabernat; C Delmas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-27       Impact factor: 3.267

5.  influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.

Authors:  M Torrico; L Aguilar; N González; M J Giménez; O Echeverría; F Cafini; D Sevillano; L Alou; P Coronel; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

6.  Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.

Authors:  David Sevillano; María-José Giménez; Emilia Cercenado; Fabio Cafini; Amadeo Gené; Luis Alou; Francesc Marco; Luis Martínez-Martínez; Pilar Coronel; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 7.  DNA fingerprinting techniques for microorganisms. A proposal for classification and nomenclature.

Authors:  M Vaneechoutte
Journal:  Mol Biotechnol       Date:  1996-10       Impact factor: 2.695

8.  Emergence of extensively drug-resistant Haemophilus parainfluenzae in Switzerland.

Authors:  Regula Tinguely; Salome N Seiffert; Hansjakob Furrer; Vincent Perreten; Sara Droz; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

9.  Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.

Authors:  L Zerva; D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

10.  Analysis of antimicrobial resistance and class 1 integrons among strains from upper respiratory tract of healthy adults.

Authors:  Haiyan Liu; Hai Wang; Mao Huang; Yaning Mei; Bing Gu; Rui Wu; Yiling Huang; Yi Chen; Yanling Xu; Tong Wang
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.